Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
BPMC

BPMC - Blueprint Medicines Corp Stock Price, Fair Value and News

106.71USD+2.84 (+2.73%)Market Closed

Market Summary

BPMC
USD106.71+2.84
Market Closed
2.73%

BPMC Alerts

  • 4 major insider sales recently.
  • Big jump in Revenue (Y/Y)
  • Big jump in Earnings (Y/Y)

BPMC Stock Price

View Fullscreen

BPMC RSI Chart

BPMC Valuation

Market Cap

6.7B

Price/Earnings (Trailing)

-23.18

Price/Sales (Trailing)

23.68

EV/EBITDA

-22.36

Price/Free Cashflow

-15.54

BPMC Price/Sales (Trailing)

BPMC Profitability

EBT Margin

-101.93%

Return on Equity

-92.79%

Return on Assets

-27.76%

Free Cashflow Yield

-6.44%

BPMC Fundamentals

BPMC Revenue

Revenue (TTM)

282.2M

Rev. Growth (Yr)

51.87%

Rev. Growth (Qtr)

33.57%

BPMC Earnings

Earnings (TTM)

-288.3M

Earnings Growth (Yr)

168.8%

Earnings Growth (Qtr)

180.36%

Breaking Down BPMC Revenue

Last 7 days

1.3%

Last 30 days

1.7%

Last 90 days

20.9%

Trailing 12 Months

74.1%

How does BPMC drawdown profile look like?

BPMC Financial Health

Current Ratio

3.76

BPMC Investor Care

Shares Dilution (1Y)

3.55%

Diluted EPS (TTM)

-4.82

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024282.2M000
2023204.6M225.6M216.2M249.4M
2022221.2M230.5M272.3M204.0M
2021640.3M486.9M333.5M180.1M
202071.9M312.5M553.1M793.7M
201950.0M55.5M61.0M66.5M
201827.2M33.0M38.7M44.5M
201726.8M25.6M27.5M21.4M
201617.6M22.0M24.7M27.8M
201500011.4M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Blueprint Medicines Corp

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 12, 2024
beckman daniella
acquired
-
-
2,242
-
Jun 12, 2024
tsai john
acquired
-
-
2,242
-
Jun 12, 2024
dable habib j
acquired
-
-
2,242
-
Jun 12, 2024
goldberg mark alan
acquired
-
-
2,242
-
Jun 12, 2024
lydon nicholas
acquired
-
-
2,242
-
Jun 12, 2024
seely lynn
acquired
-
-
2,242
-
Jun 12, 2024
albers jeffrey w.
acquired
-
-
2,242
-
Jun 12, 2024
coats lonnel
acquired
-
-
2,242
-
Jun 12, 2024
borisy alexis
acquired
-
-
2,242
-
Jun 05, 2024
carter percy h.
sold
-420,520
105
-4,000
chief scientific officer

1–10 of 50

Which funds bought or sold BPMC recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 13, 2024
NBW CAPITAL LLC
reduced
-3.4
-31,728
4,832,550
0.99%
Jun 11, 2024
EverSource Wealth Advisors, LLC
unchanged
-
-19.00
1,918
-%
Jun 04, 2024
DekaBank Deutsche Girozentrale
added
2.91
197,000
2,531,000
-%
May 28, 2024
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
reduced
-12.69
-144,000
1,267,000
0.01%
May 24, 2024
Cetera Investment Advisers
new
-
789,330
789,330
-%
May 24, 2024
FARALLON CAPITAL MANAGEMENT LLC
unchanged
-
10,480
379,440
-%
May 21, 2024
China Universal Asset Management Co., Ltd.
added
67.48
468,166
1,117,170
0.14%
May 16, 2024
Virtus Investment Advisers, Inc.
unchanged
-
1,986
71,904
0.05%
May 16, 2024
JANE STREET GROUP, LLC
added
67.08
6,650,280
15,908,600
-%
May 16, 2024
COMERICA BANK
added
2,582
990,935
1,028,190
-%

1–10 of 39

Are Funds Buying or Selling BPMC?

Are funds buying BPMC calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own BPMC
No. of Funds

Unveiling Blueprint Medicines Corp's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Apr 10, 2024
price t rowe associates inc /md/
10.2%
6,250,823
SC 13G/A
Feb 14, 2024
price t rowe associates inc /md/
8.9%
5,435,617
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Feb 08, 2024
wellington management group llp
7.03%
4,276,333
SC 13G/A
Jan 24, 2024
blackrock inc.
10.8%
6,584,176
SC 13G/A
Jan 10, 2024
vanguard group inc
10.06%
6,114,970
SC 13G/A
Nov 13, 2023
fmr llc
-
0
SC 13G/A
Feb 14, 2023
price t rowe associates inc /md/
7.2%
4,299,290
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
9.65%
5,774,456
SC 13G/A

Recent SEC filings of Blueprint Medicines Corp

View All Filings
Date Filed Form Type Document
Jun 14, 2024
4
Insider Trading
Jun 14, 2024
4
Insider Trading
Jun 14, 2024
4
Insider Trading
Jun 14, 2024
4
Insider Trading
Jun 14, 2024
4
Insider Trading
Jun 14, 2024
4
Insider Trading
Jun 14, 2024
4
Insider Trading
Jun 14, 2024
4
Insider Trading
Jun 14, 2024
4
Insider Trading
Jun 14, 2024
8-K
Current Report

Peers (Alternatives to Blueprint Medicines Corp)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
51.1B
6.8B
0.28% 3.53%
-8.56
7.46
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
19.5B
2.0B
2.99% -23.67%
-58.61
9.71
75.20% 68.82%
16.0B
2.5B
8.50% -12.61%
77.77
6.46
13.74% 186.89%
13.8B
3.8B
7.60% -2.83%
18.51
3.66
8.58% 129.81%
MID-CAP
5.2B
107.9M
-8.24% 83.94%
-9.45
48.09
54.84% -28.31%
4.9B
524.1M
-2.95% -55.09%
-11.65
9.28
394.93% 39.61%
3.6B
251.0M
-0.68% -10.56%
-12.18
14.38
73.58% -86.73%
2.9B
240.7M
-4.80% -33.39%
-6.19
12.77
-1.03% -213.92%
2.5B
813.8M
0.54% -38.22%
-1.4K
3.02
56.43% 98.83%
1.9B
996.6M
5.92% 71.39%
-4.86
1.94
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-9.22% 22.70%
27.15
4.3
60.38% -34.49%
468.2M
881.7K
-2.64% 488.84%
-13.87
481.06
-77.61% 33.36%
221.8M
4.2M
-28.67% 45.58%
-1.78
53.32
-66.30% 48.24%
19.7M
2.1M
16.67% 230.00%
-0.85
7.61
-13.45% 69.54%

Blueprint Medicines Corp News

Latest updates
MarketBeat3 hours ago
Simply Wall St11 Jun 202410:21 am
Zacks Investment Research03 May 202407:00 am

Blueprint Medicines Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue33.6%96,116,00071,957,00056,566,00057,570,00063,287,00038,781,00065,977,00036,547,00062,731,000107,021,00024,188,00027,295,00030,700,50034,106,000745,118,000375,642,5006,167,00051,533,0009,139,0005,110,0003,071,500
Costs and Expenses-1.2%174,939,000177,066,000185,546,000185,551,000187,494,000188,580,000190,254,000194,185,000168,535,000423,157,000141,284,000135,806,000121,814,000120,072,000111,751,000133,380,000119,825,000120,911,000107,100,000109,024,00090,803,000
Operating Expenses------------------120,911,000107,100,000109,024,00090,803,000
  S&GA Expenses3.9%83,557,00080,417,00070,741,00071,931,00070,950,00064,020,00057,608,00058,688,00057,058,00054,199,50049,806,00049,286,00042,002,00042,539,50037,375,00042,174,00035,655,00032,265,00025,647,00021,923,00016,553,000
  R&D Expenses-8.5%88,191,00096,434,000110,252,000110,063,000112,073,000117,839,500127,981,000128,466,000103,133,000356,876,50084,419,00080,027,00079,710,00077,404,50074,230,00091,079,00084,146,00088,646,00081,453,00087,101,00074,250,000
EBITDA Margin49.4%-1.04-2.06-2.58-2.50-2.86-2.73-2.61-2.98-2.89-3.51-1.200.720.53--------
Interest Expenses-14.0%-5,895,000-5,169,500-3,808,000-3,996,000-5,819,000-9,240,000-8,396,000427,000442,000463,000552,000633,000738,000936,0001,173,0001,586,0002,904,0002,989,5003,758,0004,275,0002,710,000
Income Taxes118.6%200,00091,500197,000200,000520,0001,051,000886,0003,100,000184,0002,346,000175,000193,000574,000688,000370,00015,00032,00055,00033,00044,00053,000
Earnings Before Taxes180.6%89,316,000-110,856,000-133,516,000-132,603,000-129,040,000-157,610,000-132,277,000-156,579,000-105,815,000-316,053,000-117,066,000-108,251,000-99,714,000-84,980,000634,348,000-123,474,000---94,275,000--
EBT Margin49.8%-1.02-2.03-2.56-2.44-2.81-2.71-2.61-3.02-2.93-3.56-1.230.700.51--------
Net Income180.4%89,136,000-110,916,500-133,713,000-132,794,000-129,560,000-158,646,000-133,163,000-159,709,000-105,999,000-318,686,000-117,241,000-108,444,000-99,714,000-85,668,500633,978,000-123,474,000-110,953,000-66,331,000-94,275,000-99,681,000-87,407,000
Net Income Margin49.8%-1.02-2.03-2.57-2.46-2.84-2.73-2.64-3.04-2.94-3.58-1.230.700.51--------
Free Cashflow-22.7%-102,617,000-83,601,000-110,734,000-133,029,000-125,545,000-122,886,000-133,619,000-120,812,000-133,879,000-15,372,000-96,592,000-63,827,000-125,951,000--------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-1.0%1,0381,0491,1051,1061,2201,3501,4581,1921,1431,2521,4771,5691,6251,7181,558817914708738807545
  Current Assets-3.9%7778088088119001,0471,228952687554772704938928842568705517514613427
    Cash Equivalents59.0%11371.0056.0076.0017012529117337.0021055453469869056528937512089.0082.0079.00
  Inventory45.8%31.0021.0016.0017.0018.0030.0035.0035.0030.0022.0017.0015.0016.009.006.004.003.00----
  Net PPE0.0%42.0042.0041.0037.0034.0033.0033.0033.0031.0031.0031.0032.0033.0034.0035.0037.0038.0038.0038.0034.0031.00
Liabilities-20.8%728919903795806835818445262281230240225248238236231243222214200
  Current Liabilities-3.9%20721519716917318317615913715012012511213111010598.0010694.0082.0065.00
    LT Debt, Current--------6.00-------------
    LT Debt, Non Current--------166-------------
Shareholder's Equity137.9%3111312033114145156407488829711,2471,3291,4001,4701,320581683464516593344
  Retained Earnings3.8%-2,250-2,339-2,229-2,095-1,962-1,832-1,674-1,541-1,381-1,275-956-839-731-631-545-1,179-1,056-945-878-784-684
  Additional Paid-In Capital3.7%2,5652,4742,4342,4112,3812,3582,3292,3032,2752,2502,2092,1742,1362,1071,8681,7621,7391,4121,3951,3761,029
Shares Outstanding2.4%63.0061.0061.0061.0060.0060.0060.0060.0059.0059.0059.0058.00---------
Float----3,803---3,004---5,150---4,234---4,628-
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-28.6%-101-78.93-104-130-122-121-129-118-132-14.11-95.60-63.16-125-24.80622-101-109-44.89-71.70-81.23-80.19
  Share Based Compensation7.3%24.0023.0023.0024.0023.0026.0024.0025.0023.0023.0024.0024.0021.0020.0020.0020.0017.0016.0015.0014.0010.00
Cashflow From Investing-2.1%77.0079.00-9.5932.00173-53.28-13277.00-41.09-346104-115132-75.53-43012.0060.0068.0075.00-24889.00
Cashflow From Financing331.2%67.0016.0098.00--2.003811771.0018.0011.0015.007.0022084.003.003102.004.003322.00
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

BPMC Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues:  
Revenue$ 96,116$ 63,287
Cost and operating expenses:  
Cost of sales3,1913,175
Research and development88,191112,073
Selling, general and administrative83,55770,950
Collaboration loss sharing 1,296
Total cost and operating expenses174,939187,494
Other income (expense):  
Interest expense, net(5,895)(5,819)
Other income, net376986
Debt extinguishment gain173,658 
Total other income (expense), net168,139(4,833)
Income (loss) before income taxes89,316(129,040)
Income tax expense180520
Net income (loss)89,136(129,560)
Other comprehensive income (loss):  
Unrealized gains (losses) on available-for-sale investments(564)5,819
Currency translation adjustments21222
Comprehensive income (loss)$ 88,784$ (123,719)
Net income (loss) per share - basic (in dollars per share)$ 1.45$ (2.15)
Net income (loss) per share - diluted (in dollars per share)$ 1.40$ (2.15)
Weighted-average number of common shares used in net income (loss) per share - basic (in shares)61,58060,126
Weighted-average number of common shares used in net income (loss) per share - diluted (in shares)63,80260,126
Product revenue, net  
Revenues:  
Revenue$ 92,525$ 39,069
Collaboration and License  
Revenues:  
Revenue$ 3,591$ 24,218

BPMC Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 113,326$ 71,286
Marketable securities534,575639,355
Accounts receivable60,04742,827
Inventory30,94021,223
Prepaid expenses and other current assets37,71433,702
Total current assets776,602808,393
Marketable securities87,70356,530
Property and equipment, net41,94741,959
Operating lease right-of-use assets, net71,22273,691
Restricted cash10,63410,238
Equity investment27,78927,789
Other assets22,57830,650
Total assets1,038,4751,049,250
Current liabilities:  
Accounts payable4,9264,710
Accrued expenses107,277127,992
Current portion of operating lease liabilities12,24011,933
Current portion of deferred revenue7,251812
Current portion of liabilities related to the sale of future royalties and revenues44,72939,198
Current portion of term loan30,18030,278
Total current liabilities206,603214,923
Operating lease liabilities, net of current portion78,48981,751
Deferred revenue, net of current portion4,6354,792
Liabilities related to the sale of future royalties and revenues, net of current portion223,090402,427
Term loan, net of current portion209,205208,535
Other long-term liabilities5,7666,213
Total liabilities727,788918,641
Commitments and Contingencies (Note 16)
Stockholders' equity:  
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.001 par value; 120,000,000 shares authorized; 62,594,247 and 61,147,236 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively6361
Additional paid-in capital2,565,2772,473,985
Accumulated other comprehensive loss(3,847)(3,495)
Accumulated deficit(2,250,806)(2,339,942)
Total stockholders' equity310,687130,609
Total liabilities and stockholders' equity$ 1,038,475$ 1,049,250
BPMC
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM and other mast cell disorders; and Fisogatinib. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEblueprintmedicines.com
 INDUSTRYBiotechnology
 EMPLOYEES660

Blueprint Medicines Corp Frequently Asked Questions


What is the ticker symbol for Blueprint Medicines Corp? What does BPMC stand for in stocks?

BPMC is the stock ticker symbol of Blueprint Medicines Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Blueprint Medicines Corp (BPMC)?

As of Tue Jun 18 2024, market cap of Blueprint Medicines Corp is 6.68 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BPMC stock?

You can check BPMC's fair value in chart for subscribers.

What is the fair value of BPMC stock?

You can check BPMC's fair value in chart for subscribers. The fair value of Blueprint Medicines Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Blueprint Medicines Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BPMC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Blueprint Medicines Corp a good stock to buy?

The fair value guage provides a quick view whether BPMC is over valued or under valued. Whether Blueprint Medicines Corp is cheap or expensive depends on the assumptions which impact Blueprint Medicines Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BPMC.

What is Blueprint Medicines Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Jun 18 2024, BPMC's PE ratio (Price to Earnings) is -23.18 and Price to Sales (PS) ratio is 23.68. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BPMC PE ratio will change depending on the future growth rate expectations of investors.